Immune Therapy for Cancer

被引:500
作者
Dougan, Michael [1 ]
Dranoff, Glenn
机构
[1] Brigham & Womens Hosp, Dept Med Oncol, Boston, MA 02115 USA
关键词
monoclonal (antibody); inflammation; vaccine; adjuvants; immunotherapy; REGULATORY T-CELLS; COLONY-STIMULATING FACTOR; GROWTH-FACTOR RECEPTOR; BACILLUS-CALMETTE-GUERIN; TUMOR-NECROSIS-FACTOR; PHASE-III TRIAL; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; LYMPHOCYTE-ASSOCIATED ANTIGEN-4; HELICOBACTER-PYLORI INFECTION; METASTATIC BREAST-CANCER;
D O I
10.1146/annurev.immunol.021908.132544
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Over the past decade, immune therapy has become a standard treatment for a variety of cancers. Monoclonal antibodies, immune adjuvants, and vaccines against oncogenic viruses are now well-established cancer therapies. Immune modulation is a principal element of supportive care for many high-dose chemotherapy regimens. In addition, immune activation is now appreciated as central to the therapeutic mechanism of bone marrow transplantation for hematologic malignancies. Advances in our understanding of the molecular interactions between tumors and the immune system have led to many novel investigational therapies and continue to inform efforts for devising more potent therapeutics. Novel approaches to immune-based cancer treatment strive to augment antitumor immune responses by expanding tumor-reactive T cells, providing exogenous immune-activating stimuli, and antagonizing regulatory pathways that induce immune tolerance. The future of immune therapy for cancer is likely to combine many of these approaches to generate more effective treatments.
引用
收藏
页码:83 / 117
页数:35
相关论文
共 239 条
[31]   Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets [J].
Clynes, RA ;
Towers, TL ;
Presta, LG ;
Ravetch, JV .
NATURE MEDICINE, 2000, 6 (04) :443-446
[32]   Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].
Cobleigh, MA ;
Vogel, CL ;
Tripathy, D ;
Robert, NJ ;
Scholl, S ;
Fehrenbacher, L ;
Wolter, JM ;
Paton, V ;
Shak, S ;
Lieberman, G ;
Slamon, DJ .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648
[33]   Agonist anti-GITR antibody enhances vaccine-induced CD8+ T-cell responses and tumor immunity [J].
Cohen, AD ;
Diab, A ;
Perales, MA ;
Wolchok, JD ;
Rizzuto, G ;
Merghoub, T ;
Huggins, D ;
Liu, CL ;
Turk, MJ ;
Restifo, NP ;
Sakaguchi, S ;
Houghton, AN .
CANCER RESEARCH, 2006, 66 (09) :4904-4912
[34]   FDA drug approval summary:: Bevacizumab (Avastin®) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer [J].
Cohen, Martin H. ;
Gootenberg, Joe ;
Keegan, Patricia ;
Pazdur, Richard .
ONCOLOGIST, 2007, 12 (06) :713-718
[35]   FDA drug approval summary: Bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer [J].
Cohen, Martin H. ;
Gootenberg, Joe ;
Keegan, Patricia ;
Pazdur, Richard .
ONCOLOGIST, 2007, 12 (03) :356-361
[36]   CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].
Coiffier, B ;
Lepage, E ;
Brière, J ;
Herbrecht, R ;
Tilly, H ;
Bouabdallah, R ;
Morel, P ;
Van den Neste, E ;
Salles, G ;
Gaulard, P ;
Reyes, F ;
Gisselbrecht, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242
[37]   The inhibitory cytokine IL-35 contributes to regulatory T-cell function [J].
Collison, Lauren W. ;
Workman, Creg J. ;
Kuo, Timothy T. ;
Boyd, Kelli ;
Wang, Yao ;
Vignali, Kate M. ;
Cross, Richard ;
Sehy, David ;
Blumberg, Richard S. ;
Vignali, Dario A. A. .
NATURE, 2007, 450 (7169) :566-U19
[38]   Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival [J].
Curiel, TJ ;
Coukos, G ;
Zou, LH ;
Alvarez, X ;
Cheng, P ;
Mottram, P ;
Evdemon-Hogan, M ;
Conejo-Garcia, JR ;
Zhang, L ;
Burow, M ;
Zhu, Y ;
Wei, S ;
Kryczek, I ;
Daniel, B ;
Gordon, A ;
Myers, L ;
Lackner, A ;
Disis, ML ;
Knutson, KL ;
Chen, LP ;
Zou, WP .
NATURE MEDICINE, 2004, 10 (09) :942-949
[39]   Tregs and rethinking cancer immunotherapy [J].
Curiel, Tyler J. .
JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (05) :1167-1174
[40]   Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells [J].
Dannull, J ;
Su, Z ;
Rizzieri, D ;
Yang, BK ;
Coleman, D ;
Yancey, D ;
Zhang, AJ ;
Dahm, P ;
Chao, N ;
Gilboa, E ;
Vieweg, J .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (12) :3623-3633